Merck - PRWeb Press Release Group http://www.rsspad.com/rss2/31023.xml Merck - Powered by PRWeb and RSSPad en xml@emediawire.com xml@emediawire.com 30 New Indication for SINGULAIR® (montelukast sodium) Approved to Prevent Exercise-Induced Bronchoconstriction http://www.prweb.com/releases/2007/04/prweb521963.htm Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for SINGULAIR® (montelukast sodium) to prevent exercise-induced bronchoconstriction (EIB; also known as exercise-induced asthma) in patients aged 15 years and older. SINGULAIR is the first and only oral tablet approved for this use. (PRWeb Apr 26, 2007)

Read the full story at http://www.prweb.com/releases/2007/04/prweb521963.htm

]]> Thu, 26 Apr 2007 07:00:00 GMThttp://www.prweb.com/releases/2007/04/prweb521963.htm FDA Approves ZOLINZA for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-cell Lymphoma Who Have Tried and Failed Other Therapies http://www.prweb.com/releases/2006/10/prweb447908.htm ZOLINZA is Merck's first anticancer treatment in decades to be approved by the FDA (PRWeb Oct 8, 2006)

Read the full story at http://www.prweb.com/releases/2006/10/prweb447908.htm

]]> Sun, 08 Oct 2006 07:00:00 GMThttp://www.prweb.com/releases/2006/10/prweb447908.htm FDA Approves ZOSTAVAX®, Merck’s New Vaccine for Prevention of Shingles in Adults Age 60 and Older http://www.prweb.com/releases/2006/05/prweb391124.htm ZOSTAVAX is the first and only medical option for preventing shingles, a painful disease that can occur in anyone who has had chickenpox. (PRWeb May 26, 2006)

Read the full story at http://www.prweb.com/releases/2006/05/prweb391124.htm

]]> Fri, 26 May 2006 07:00:00 GMThttp://www.prweb.com/releases/2006/05/prweb391124.htm